![conference banner](/images/conference-banner.jpeg)
Abstract
Thrombin activatable fibrinolysis inhibitor (TAFI) is a zymogene that potently inhibits fibrinolysis. It is synthesized by the liver and has an inhibitor role in fibrinolysis through the removal of the carboxy-terminal lysine and arginine residues from partially degraded fibrin polymers. Besides, TAFI has a suppressor effect on conversion of inactive plasminogen to plasmin. Alterations in TAFI pathway have been reported in many conditions. Few data are present in the literature regarding the relationship between TAFI and endocrine disorders. The results from few studies in patients with cardiovascular disease are conflicting. Understanding the role of TAFI in the pathogenesis of endocrine and cardiovascular disorders may hold promise for improving management of these diseases. This paper includes a review of the studies and patents concerned with TAFI pathway and endocrine and cardiovascular problems.
Keywords: Thrombin activatable fibrinolysis inhibitor, endocrine, coronary artery disease, stroke, thyroid, oestrogen
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)
Title: Role of Thrombin Activatable Fibrinolysis Inhibitor in Endocrine and Cardiovascular Disorders
Volume: 2 Issue: 1
Author(s): Baris Akinci and Sena Yesil
Affiliation:
Keywords: Thrombin activatable fibrinolysis inhibitor, endocrine, coronary artery disease, stroke, thyroid, oestrogen
Abstract: Thrombin activatable fibrinolysis inhibitor (TAFI) is a zymogene that potently inhibits fibrinolysis. It is synthesized by the liver and has an inhibitor role in fibrinolysis through the removal of the carboxy-terminal lysine and arginine residues from partially degraded fibrin polymers. Besides, TAFI has a suppressor effect on conversion of inactive plasminogen to plasmin. Alterations in TAFI pathway have been reported in many conditions. Few data are present in the literature regarding the relationship between TAFI and endocrine disorders. The results from few studies in patients with cardiovascular disease are conflicting. Understanding the role of TAFI in the pathogenesis of endocrine and cardiovascular disorders may hold promise for improving management of these diseases. This paper includes a review of the studies and patents concerned with TAFI pathway and endocrine and cardiovascular problems.
Export Options
About this article
Cite this article as:
Akinci Baris and Yesil Sena, Role of Thrombin Activatable Fibrinolysis Inhibitor in Endocrine and Cardiovascular Disorders, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) 2008; 2 (1) . https://dx.doi.org/10.2174/187221408783421327
DOI https://dx.doi.org/10.2174/187221408783421327 |
Print ISSN 1872-2148 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3334 |
Related Articles
-
Dynamic Role of Macrophage Sub Types on Development of Atherosclerosis
and Potential Use of Herbal Immunomodulators as Imminent
Therapeutic Strategy
Cardiovascular & Hematological Agents in Medicinal Chemistry Possible Therapeutic Targets in Cardiac Myocyte Apoptosis
Current Pharmaceutical Design Physiological Roles for K posative Channels and Gap Junctions in Urogenital Smooth Muscle Implications for Improved Understanding of Urogenital Function, Disease and Therapy
Current Drug Targets Modulation of Neutrophil Function by Hormones
Current Immunology Reviews (Discontinued) Syntheses of 2,3-Diarylated 2H-Benzo[e][1,2]Thiazine 1,1-Dioxides and their 3,4-Dihydro Derivatives, and Assessment of their Inhibitory Activity Against MCF-7 Breast Cancer Cells
Medicinal Chemistry COVID-19 Vaccine Practices and Perceptions Among an Academic Healthcare Community
Coronaviruses A Study and Analysis of Disease Identification using Genomic Sequence Processing Models: An Empirical Review
Current Genomics Comparative Study of Nutritional and Phytochemical Attributes of Andrographis paniculata, Bryophyllum pinnatum and Clitoria ternatea for Nutraceutical Applications
Current Nutrition & Food Science Matrix Metalloproteinases in Respiratory Diseases: From Pathogenesis to Potential Clinical Implications
Current Medicinal Chemistry Flavonoids for Allergic Diseases: Present Evidence and Future Perspective
Current Pharmaceutical Design Evaluation and Clinical Implication of Zhenwu Decoction on Seven Cytochrome P450 Enzyme in Chronic Heart Failure Rats
Current Drug Metabolism The Role of Inflammation in Epicardial Adipose Tissue in Heart Diseases
Current Pharmaceutical Design Nanotechnology-based Drug Delivery, Metabolism and Toxicity
Current Drug Metabolism Transseptal Access to the Left Atrium: Tips and Tricks to Keep it Safe Derived from Single Operator Experience and Review of the Literature
Current Cardiology Reviews Editorial: Ischemic Stroke Prevention
Current Vascular Pharmacology Gene Therapy for Familial Hypercholesterolemia
Current Pharmaceutical Design The Potentials of Selected Therapeutic Targets for Inflammation: A Snapshot
Recent Patents on Inflammation & Allergy Drug Discovery The Potential of Secondary Metabolites from Plants as Drugs or Leads Against Protozoan Neglected Diseases – Part I
Current Medicinal Chemistry Diagnosis and Management of Heart Failure with Preserved Ejection Fraction: 10 Key Lessons
Current Cardiology Reviews Classical and New Renin-Angiotensin Signalling in Atherosclerosis
Current Signal Transduction Therapy